SCHEMBL5413822

SCHEMBL5413822

CCC(=O)Nc1cnc(Nc2ccc(Cl)c(Cl)c2)nc1NC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.53
▸ MAP3K7 O43318 2/20 0.49
▸ EGFR P00533 2/20 0.48
▸ JAK3 P52333 1/20 0.48
▸ BMX P51813 2/20 0.48
▸ DDR1 Q08345 1/20 0.48
▸ MAPK14 Q16539 1/20 0.48
▸ STK17A Q9UEE5 2/20 0.47
▸ STK17B O94768 1/20 0.47
▸ HDAC3 O15379 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ CACNA1B Q00975 1/20 0.45
▸ APBA1 Q02410 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ BRD4 O60885 1/20 0.45
▸ MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5416362 0.89 STK17A (0.46) CYP3A4MAP3K7STK17ASTK17BHDAC3
SCHEMBL5416062 0.88 STK17A (0.44) MAP3K7EGFRSTK17ASTK17BHDAC3
SCHEMBL5415948 0.87 HDAC3 (0.49) CYP3A4EGFRSTK17ASTK17BHDAC3
SCHEMBL5415300 0.87 BRD4 (0.46) CYP3A4EGFRJAK3MAPK14STK17A
SCHEMBL5408198 0.86 HDAC3 (0.48) STK17ASTK17BHDAC3HDAC1HDAC2
SCHEMBL5415421 0.86 STK17A (0.48) STK17ASTK17BHDAC3HDAC1HDAC2
SCHEMBL5414041 0.86 STK17A (0.44) CYP3A4EGFRSTK17ASTK17BHDAC3
SCHEMBL5415230 0.86 EGFR (0.48) EGFRMAPK14STK17ASTK17BHDAC3
SCHEMBL5418427 0.85 HDAC3 (0.47) EGFRSTK17ASTK17BHDAC3HDAC1
SCHEMBL5410091 0.84 APEX1 (0.53) STK17ASTK17BHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 CYP3A4 733/4885MAP3K7 4437/4885EGFR 3316/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 CYP3A4 545/4885MAP3K7 4222/4885EGFR 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback